Previously we presented a simplified procedure for empirically finding metabolites which can reverse significantly the toxicity of antibiotics and other inhibitors of bacteria (Foster and Pittillo, 1953b of the inhibitors used was the spread plate method described previously (Foster and Pittillo, 1953a,b). Washed agar was used. In certain cases the auxanographic methods were used to screen the 50-odd pure metabolites for reversal powers. The compounds tested were the same as those listed previously (Foster and Pittillo, 1953b) . Although Escherichia coli, strain B, had been used previously, we use Aerobacter aerogenes, strain P, routinely now because it grows faster. A nonpathogenic strain of Mycobacterium, no. AF 2, was employed also in special experiments as designated. Owing to difficulty in obtaining growth on plates with the small inoculum desired, these were conducted in synthetic broth medium (Youmans, 1944) containing 0.1 per cent "tween 80". Tubes were read after shaking 48 hours at 37C.
Previously we presented a simplified procedure for empirically finding metabolites which can reverse significantly the toxicity of antibiotics and other inhibitors of bacteria (Foster and Pittillo, 1953b) . Having surveyed a considerable number of inhibitors, both antibiotics and synthetics, we have concluded that many inhibitors are apt to have their action reversed by one or more known or unknown (yeast extract) metabolites. Frequently the degree of reversal is very small, but demonstrable. Implicit in such results is the idea that the inhibitor exerts its toxic effect on the susceptible cells through interference with the synthesis or utilization by the cell of the specific reversing metabolite(s).
It seemed logical that if two chemically dissimilar inhibitors could be found whose toxicities separately are reversible by one and the same metabolite, the two inhibitors would function synergistically in inhibiting the particular bacterium. Thus, without any knowledge of the biosynthetic pathways involved, one would have an empirical approach for potentiation of drug action. Synergistic action would be expected only if the sites of inhibition of the two drugs are different in connection with the particular metabolite. On a chance basis, they are apt to be, and the frequency of synergism demonstrable by this approach bears out that conclusion. In essence, this approach embodies a rationale for some instances of synergistic action and, more particularly, presents a simple procedure whereby deliberate potentiation of an inhibitor reversible by a metabolite might be achieved.
MATERIALS AND METHODS
The procedure for screening pure metabolites having the power to reverse otherwise toxic levels 1 Supported by a grpnt from the WilliamsWaterman Fund for Dietary Diseases and in part by a grant-in-aid from the American Cancer Society upon recommendation of the Committee on Growth of the National Research Council. of the inhibitors used was the spread plate method described previously (Foster and Pittillo, 1953a,b) . Washed agar was used. In certain cases the auxanographic methods were used to screen the 50-odd pure metabolites for reversal powers. The compounds tested were the same as those listed previously (Foster and Pittillo, 1953b) . Although Escherichia coli, strain B, had been used previously, we use Aerobacter aerogenes, strain P, routinely now because it grows faster. A nonpathogenic strain of Mycobacterium, no. AF 2, was employed also in special experiments as designated. Owing to difficulty in obtaining growth on plates with the small inoculum desired, these were conducted in synthetic broth medium (Youmans, 1944) Grundy et al. (1952) .
Synergism experinmns with A. aerogenes. Each pair of inhibitors (table 1), the individuals of which were reversed by a common metabolite, was tested in a cross-concentration experiment. The levels were varied by factors of two in the "A" pair and by factors of three in the "B" and "C" pairs. Two identical series were conducted for each experiment, one series without the reversing agent and one with the reversing agent present in the basal medium.
In the absence of the reversing metabolite phenylalanine it took ( (Beerstecher and Shive, 1947; Potter, 1951) . How broadly this interpretation and mechanism may apply to inhibitor synergism in general remains to be seen, but it is of interest that in every case where we have predicted synergism between two inhibitors reversed alike by the same metabolite, synergism was obtained. Heretofore, synergism in inhibitor action has been achievable by (1) mainly chance results from random testing of combinations of inhibitors (Jawetz et al., 1952) without knowledge of mechanisms involved; and (2) very rarely, in case where details of a biochemical pathway are known by selecting two inhibitors interfering at different stages on that single biosynthetic pathway (Beerstecher and Shive, 1947; Potter, 1951) . Of interest in connection with (1) above is the finding that in the case of antibiotics known to be potentially synergistic, this property appears to be displayed more frequently when the test bacteria developed resistance rapidly after growth in each of the two antibiotics (Klein and Schorr, 1953) . The apparent lack of emphasis on approach (2) above (Woolley, 1952; Work and Work, 1948) indicates that its possibilities have been limited to those few cases where pathways are known adequately and where appropriate synthetic analogues are available to apply to the test. The rationale described herein should permit more illustrations of this type to be obtained empirically.
In the light of a considerable amount of new data, it is likely that the potentiation of aureomycin caused by 1 ,2-dichloro4,5-diaminobenzene was not entirely "protected inhibition" on account of the fact that both inhibitors did inhibit riboflavin synthesis (Foster and Pittillo, 1953b) . However, because aureomycin also inhibited the utilization of riboflavin, which reversed aureomycin inhibition, the extent to which 1 ,2-dlchloro4,5-diaminobenzene blocks the synthesis of riboflavin involved here would be regarded as "protected inhibition" (see below).
Speaking strictly, one could regard those instances of synergism in drug inhibition which are reversible by a single metabolite as interpretable in terms of two types of mecanisms. First is sequential blocking where each inhibitor blocks the pathway of biosynthesis of the reversing metabolite at different points. The isonicotianic hydrazide-actathiazic acid synergism described here is a good case in point.
Second, would be "protected inhibition", where drug "Y" inhibits the synthesis of a metabolite which reverses inhibition caused by "X" drug. The intrinsic inhibitory power of "X" is not idisplayed owing to its reversal by the metabolite. Inhibition of synthesis of the latter by "Y" thus "protects" the intrinsic inhibitory power of "X", hence protected inhibition. A good illustration appears to be the tyrosine-,6-hydroxyphenylalanine synergistic inhibition of E. coli (Beerstecher and Shive, 1947) although that paper did not actually show that synergism was reversed by phenylalnine. ,6-Hydroxyphenylalanine inhibited by preventing the functioning of phenylalanine in an enzyme system; phenylalanine reversed this inhibitor. Tyrosine prevented the biosynthesis of phenylalanine. However, protected inhibition as a mechanism of potentiating drug action has a broader basis than synergism alone. It would apply to any instance where a reversing metabolite for a particular drug is known and to any method for reducing the concentration of that metabolite, to allow the intrinsic inhibitory power of the drug to be exhibited. Apart from inhibition of its synthesis by another drug, theoretically, protected inhibition could be achieved by (1) destruction of the reversing agent. This was proposed to explain potentiation of sulfanilamide action by azochloramide (Neter, 1942;  Schmelkes and Wyss, 1942) ; however, this interpretation has been disputed (Kohn, 1943) 
SUMMARY
The toxicity of dihydrostreptomycin and of Ltyrosine for Aerobacter aerogenes and for Mycobacterium, strain AF 2, was reversed to a significant degree by L-phenylalanine. The toxicities of isonicotinic hydrazide and of actathiazic acid for the same two organisms were reversed by biotin as well as other "B" vitamins. The toxicities of antibiotic 106-7 and of aureomycin for A. aerogenes were reversed by glycine. The compounds reversed by the same metabolite were synergistically inhibitory when combined. In each case the synergism was reduced significantly in the presence of the reversing metabolite. Isonicotinic hydrazide and actathiazic acid each inhibited biosynthesis of biotin by A. aerogenes, determined by Lacbacillus arabinosus assay. Interpretation of and a rationale for obtaining potentiation of inhibitor action are presented.
ADDENDUM
After the galley proof of this paper was received, the following publication came to our attention in which the competitive antagonism between biotin and isonicotinic hydraside was described for Mycobacterium tuberculois: "Inibizione della Crescita di M. Tbc. da Antagonistic di Biotina", A. DiMarco, B. Zanchi and V. Savaglio, Sperimentale 120, fasc. XI-XII, 339-346 (1952) .
